Peptide-antisense oligonucleotide (ASO) conjugates represent a cutting-edge approach in nucleic acid therapeutics, combining the sequence-specific gene silencing or splice-modulating capacity of antisense oligonucleotides with the tissue-targeting and cell-penetrating properties of peptide carriers. By covalently linking peptides to chemically modified oligonucleotides, researchers have overcome longstanding delivery barriers that have historically limited the clinical translation of ASO drugs. This conjugation strategy has proven particularly impactful for neutral-backbone oligonucleotides such as phosphorodiamidate morpholino oligomers (PMOs) and peptide nucleic acids (PNAs), which resist nuclease degradation but display poor cellular uptake without carrier assistance.
The field has matured rapidly, with multiple peptide-ASO conjugates advancing into preclinical and clinical evaluation for neuromuscular disorders, central nervous system (CNS) diseases, and oncology indications. Creative Peptides offers comprehensive ASO Peptide Conjugate synthesis services that support researchers in designing, conjugating, and characterizing peptide-ASO constructs for diverse therapeutic applications. This article provides a detailed examination of PMO-peptide, PNA-peptide, and splice-switching oligonucleotide conjugates, covering their chemistry, design principles, applications, analytical methods, and the manufacturing partnerships that enable their development.
Antisense oligonucleotides exert their therapeutic effects through three principal mechanisms, each defined by the chemistry of the oligonucleotide backbone and the intracellular compartment in which target engagement occurs. The RNase H-dependent mechanism relies on DNA-like ASO sequences (typically gapmers with a central DNA stretch flanked by modified nucleotides) that form DNA:RNA heteroduplexes with target mRNA, recruiting RNase H1 to cleave the RNA strand and promote degradation. This mechanism operates predominantly in the nucleus but also functions in the cytoplasm, leading to robust target knockdown. Steric block mechanisms, in contrast, employ fully modified ASO chemistries such as PMOs, 2'-O-methoxyethyl (2'-MOE), or locked nucleic acid (LNA) oligomers that bind to RNA without triggering enzymatic cleavage, instead physically obstructing translation initiation, polyadenylation, or other RNA processing events.
Splice modulation represents a specialized steric block application wherein ASOs target splice sites, branch points, or regulatory sequences to redirect pre-mRNA splicing, producing alternative mRNA isoforms that restore functional protein expression or eliminate disease-causing transcripts. This mechanism is exquisitely dependent on nuclear localization, as pre-mRNA splicing occurs in the nucleus before mature mRNA is exported. Peptide conjugation enhances the nuclear delivery of splice-switching oligonucleotides (SSOs), making peptide-ASO conjugates particularly attractive for exon-skipping therapies in Duchenne muscular dystrophy (DMD) and splice-correction strategies for spinal muscular atrophy (SMA).
The structural landscape of antisense oligonucleotides encompasses a diverse range of backbone and sugar modifications, each offering distinct pharmacological properties that influence conjugation strategy and therapeutic application. PMOs feature a morpholine ring replacing the ribose sugar and phosphorodiamidate linkages replacing phosphodiester bonds, yielding an uncharged, nuclease-resistant backbone with high target affinity but negligible protein binding and poor cellular uptake. PNAs replace the entire sugar-phosphate backbone with a polyamide (N-(2-aminoethyl)glycine) scaffold, producing an achiral, neutral oligomer with exceptional hybridization strength and complete resistance to enzymatic degradation but very limited solubility and cellular permeability.
Charged ASO chemistries include phosphorothioate (PS)-modified oligomers, which substitute a sulfur atom for a non-bridging oxygen in the phosphate linkage, enhancing nuclease resistance and promoting protein binding that facilitates tissue distribution but occasionally introduces off-target effects. Sugar modifications such as 2'-MOE, LNA, and constrained ethyl (cEt) further increase target affinity and metabolic stability while maintaining compatibility with RNase H recruitment in gapmer designs. The choice of ASO chemistry fundamentally dictates conjugation chemistry, linker requirements, and the overall biophysical behavior of the peptide-ASO conjugate. Creative Peptides provides expert guidance in Peptide-RNA Conjugation across these diverse chemistries, ensuring optimal pairing of peptide carriers with the appropriate oligonucleotide platform.
Despite their high target specificity and favorable pharmacokinetic properties, most antisense oligonucleotides exhibit poor spontaneous cellular uptake due to their size, charge, and hydrophilicity, which prevent passive diffusion across lipid bilayer membranes. Even PS-modified ASOs, which bind serum proteins and achieve broad tissue distribution, accumulate predominantly in endosomal and lysosomal compartments where they remain sequestered and functionally inactive unless they escape to the cytosol or nucleus. Neutral backbone chemistries such as PMOs and PNAs face an even greater delivery challenge, as they lack the protein-binding properties that promote PS-ASO tissue distribution and rely almost entirely on carrier-mediated delivery for cellular entry.
Cell-penetrating peptides (CPPs), typically 8 to 30 amino acids in length and rich in arginine or lysine residues, address this delivery bottleneck by facilitating endocytic uptake and, critically, promoting endosomal escape of conjugated cargo into the cytosolic and nuclear compartments. CPP-ASO conjugates have demonstrated orders-of-magnitude improvements in cellular delivery compared to naked oligonucleotides, enabling therapeutic activity at clinically feasible doses. The growing recognition that delivery, rather than target affinity or specificity, constitutes the primary barrier to ASO efficacy has positioned peptide conjugation as an essential enabling technology for the next generation of oligonucleotide therapeutics.
PMO-peptide conjugates represent the most clinically advanced class of peptide-ASO conjugates, with extensive validation in preclinical models of neuromuscular disease and early-phase clinical trials. The uncharged PMO backbone is chemically compatible with a wide range of conjugation chemistries, enabling covalent attachment of CPPs at either terminus without compromising hybridization or splice-modulating activity.
Phosphorodiamidate morpholino oligomers are synthetic DNA analogs in which the ribofuranose ring is replaced by a morpholine heterocycle and the phosphodiester linkage is substituted with a phosphorodiamidate group. This structural transformation eliminates the negative charge characteristic of natural nucleic acids, producing an oligomer that is electrically neutral, highly resistant to nucleases and proteases, and capable of forming stable duplexes with complementary RNA sequences. The neutral backbone significantly simplifies conjugation chemistry because there is no electrostatic repulsion between the oligonucleotide and positively charged CPPs during coupling reactions, unlike the situation with negatively charged PS-ASOs where charge neutralization and aggregation must be carefully managed.
PMOs are typically synthesized on solid supports with a free amine or thiol handle introduced at the 5' or 3' terminus during automated synthesis, providing a reactive site for site-specific conjugation to peptide carriers. The most common conjugation strategies employ heterobifunctional crosslinkers containing maleimide-thiol chemistry (for cysteine-terminated CPPs) or activated ester-amine chemistry (for N-terminal conjugation), often incorporating a cleavable or non-cleavable linker to modulate intracellular release kinetics. The modularity of PMO conjugation means that libraries of peptide-PMO conjugates can be rapidly screened for activity, a significant advantage for structure-activity relationship studies and lead optimization. Creative Peptides' Click Chemistry services further expand the conjugation toolkit, enabling bioorthogonal ligation strategies that proceed under mild conditions with high chemoselectivity.
The iterative optimization of CPP sequences for PMO delivery has yielded several high-performance peptide carriers, with the Pip (peptide nucleic acid/PMO internalization peptide) series developed by Gait and colleagues standing as the most extensively characterized. Pip6a, a 24-amino acid arginine-rich peptide containing a hydrophobic core motif (YQFLI), achieves exceptional exon-skipping activity in both skeletal and cardiac muscle when conjugated to PMOs targeting DMD exon 23 or exon 51. Structure-activity studies have revealed that the hydrophobic core is essential for endosomal escape, while the arginine residues drive cell surface binding and endocytic uptake, together producing a synergistic delivery mechanism that outperforms simple polyarginine peptides by more than an order of magnitude.
Other notable CPP-PMO systems include the B-peptide series (RVG-9R for brain targeting), the DG9 peptide with broad tissue distribution, and the (RXR)4 peptide series with optimized spacing of arginine residues for enhanced proteoglycan binding. Each CPP class offers distinct tissue tropism and endosomal escape properties, providing researchers with a palette of delivery options that can be matched to the therapeutic target tissue and required level of exon-skipping efficiency. Conjugation of these optimized CPPs to PMOs is typically achieved through a modular synthesis workflow that enables parallel production and screening of multiple CPP-PMO variants, accelerating the identification of lead conjugates for specific disease indications.
Duchenne muscular dystrophy has served as the primary clinical driver for CPP-PMO conjugate development, with exon-skipping strategies designed to restore the dystrophin reading frame in patients harboring amenable DMD gene deletions. The FDA approval of eteplirsen (an unmodified PMO targeting exon 51) established the clinical viability of PMO-mediated exon skipping, but the modest dystrophin restoration levels achieved with naked PMOs (typically 0.5-5% of normal) have motivated the development of CPP-PMO conjugates with substantially enhanced tissue delivery. Preclinical studies of Pip6a-PMO conjugates targeting exon 23 in the mdx mouse model have demonstrated dystrophin restoration exceeding 50% of normal levels in both skeletal muscle and cardiac tissue, a result that far surpasses the performance of unconjugated PMOs administered at equivalent doses.
Translational efforts have extended beyond DMD to include CPP-PMO conjugates for myotonic dystrophy type 1, where PMOs targeting the expanded CUG repeat in DMPK mRNA can displace sequestered MBNL1 protein and reverse splicing pathology. The safety profile of CPP-PMOs has been evaluated in multiple animal species, with dose-limiting toxicities primarily associated with high cationic charge density leading to transient kidney accumulation and tubular effects, observations that have guided the design of next-generation CPPs with moderated charge properties. These clinical-translational advances highlight the importance of robust manufacturing partnerships, and Creative Peptides' Peptide-oligonucleotide Conjugation services provide the quality and scalability required for translational research programs.
PNA-peptide conjugates exploit the unique polyamide backbone of peptide nucleic acids, which combines the sequence-specific recognition properties of natural nucleic acids with the chemical versatility and stability of peptide chemistry. The achiral, uncharged PNA structure makes it an ideal partner for peptide conjugation, as both components can be synthesized using solid-phase peptide synthesis (SPPS) methods, enabling seamless production of chimeric peptide-PNA constructs in a single synthetic workflow.
Peptide nucleic acids replace the sugar-phosphate backbone of DNA with an N-(2-aminoethyl)glycine polyamide scaffold to which the nucleobases (adenine, guanine, cytosine, and thymine) are attached via methylenecarbonyl linkers. This structural substitution produces an oligomer that retains the base-pairing specificity of natural nucleic acids while eliminating the phosphate negative charges entirely, resulting in a molecule that forms exceptionally stable duplexes and triplexes with complementary DNA and RNA sequences. The polyamide backbone is completely resistant to nucleases and proteases, conferring extraordinary metabolic stability that can extend the in vivo half-life of PNA-based therapeutics beyond that of conventional oligonucleotides.
A significant practical advantage of PNA chemistry is its compatibility with standard solid-phase peptide synthesis protocols using Fmoc- or Boc-protected PNA monomers, meaning that PNA-peptide conjugates can be assembled on a single resin in a continuous synthesis without the need for postsynthesis conjugation steps. This synthetic convergence simplifies production, improves yield consistency, and enables precise control over conjugation site, stoichiometry, and linker chemistry. However, the neutral, hydrophobic character of PNAs also presents challenges including limited aqueous solubility, a tendency to aggregate, and poor cellular uptake, all of which can be effectively mitigated through covalent attachment of solubilizing and cell-penetrating peptide sequences.
CPP-PNA conjugates have been deployed in both antisense and antigene strategies, the former targeting mRNA in the cytoplasm or nucleus and the latter targeting chromosomal DNA to form triplex structures that block transcription. In antisense applications, CPP-PNA conjugates sterically block translation initiation or elongation by binding to the start codon region or coding sequence of target mRNAs, achieving sequence-specific protein knockdown without recruiting RNase H. The absence of RNase H activation can be advantageous because it reduces off-target cleavage of partially complementary transcripts, enhancing the specificity profile compared to DNA gapmer ASOs.
Antigene applications exploit the unique ability of homopyrimidine PNAs to invade double-stranded DNA and form stable PNA-DNA-PNA triplex structures that physically block RNA polymerase progression, effectively silencing gene expression at the transcriptional level. This strategy has been applied to downregulate oncogenes, viral genes, and disease-associated genes that are difficult to target with conventional small-molecule or protein-based therapeutics. Effective antigene targeting requires nuclear localization of the PNA conjugate, a requirement well served by CPPs containing nuclear localization signals (NLSs) or by arginine-rich CPPs that naturally accumulate in the nucleolus and nucleoplasm.
PNA-peptide conjugates have demonstrated remarkable efficacy as splice-correction agents, particularly in models of beta-thalassemia where PNAs targeting aberrant splice sites in the beta-globin pre-mRNA restore correct splicing and functional hemoglobin production. The high-affinity binding and nuclease resistance of PNAs are particularly advantageous for splice correction, as they ensure persistent occupancy of target splice sites without degradation, allowing sustained redirection of the splicing machinery. CPP-PNA conjugates designed to block cryptic splice sites activated by intronic mutations have achieved splice correction at nanomolar concentrations in cell culture models, positioning them as viable candidates for genetic diseases caused by splicing defects.
Beyond splice correction, PNA-peptide conjugates have been adapted as gene editing tools when combined with donor DNA templates for targeted gene modification. The ability of bis-PNA molecules to form stable triplex structures at genomic target sites has been exploited to recruit DNA repair machinery and stimulate homologous recombination, enabling site-specific correction of disease-causing point mutations. Furthermore, PNA-peptide conjugates have been integrated into CRISPR-based systems as guide replacements or delivery vehicles, combining the sequence-programmable targeting of PNAs with the enzymatic activity of Cas nucleases for enhanced genome editing specificity. The versatility of the PNA platform across these diverse applications underscores the value of robust conjugation chemistry, which Creative Peptides supports through its Peptide Linker Design expertise.
Peptide conjugation to 2'-modified ASOs, including 2'-O-methoxyethyl (2'-MOE), locked nucleic acid (LNA), and constrained ethyl (cEt) chemistries, addresses the delivery limitations of these high-affinity, nuclease-resistant oligonucleotide platforms. Unlike neutral PMOs and PNAs, 2'-modified ASOs typically incorporate a phosphorothioate backbone that introduces negative charge and protein-binding properties, creating distinct conjugation challenges and opportunities that must be carefully managed to preserve therapeutic activity.
The 2'-MOE modification, in which a methoxyethyl group is appended to the 2'-position of the ribose sugar, increases target RNA binding affinity by approximately 2-3 degrees Celsius per modification while conferring substantial nuclease resistance and reducing the immunostimulatory potential of the oligonucleotide. LNA chemistry achieves even greater affinity gains (5-8 degrees Celsius per modification) through a methylene bridge that locks the ribose in the C3'-endo conformation preorganized for RNA binding, while cEt chemistry provides intermediate affinity with improved tolerability profiles. These modifications are typically deployed in gapmer designs where a central DNA stretch recruits RNase H, flanked by 2'-modified wings that confer stability and affinity.
Conjugation of peptides to 2'-modified ASOs can be accomplished at the 5' or 3' terminus, at internal positions within the oligonucleotide sequence, or through pendant linkers attached to modified nucleobases. Terminal conjugation is generally preferred because it minimizes interference with Watson-Crick base pairing and RNase H recruitment, though internal conjugation sites can be strategically positioned in nonessential regions to achieve multivalent peptide display. The polyanionic character of PS-ASOs requires careful attention to stoichiometry and charge balance during conjugation, as excess cationic peptide can induce aggregation or precipitation through electrostatic complexation. Creative Peptides' CPP Synthesis capabilities provide researchers with a wide range of CPP scaffolds optimized for charged oligonucleotide delivery.
Terminal conjugation of peptides to PS-ASOs is most commonly achieved through amino-modified linkers introduced at the 5' terminus during the final coupling step of solid-phase oligonucleotide synthesis, using commercially available amino-modifier phosphoramidites. The resulting 5'-amino ASO can be reacted with heterobifunctional crosslinkers such as SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) or its sulfonated analog sulfo-SMCC, which introduce a maleimide group for subsequent reaction with cysteine-thiol-containing peptides. Alternatively, click chemistry approaches employing copper-catalyzed azide-alkyne cycloaddition (CuAAC) or strain-promoted azide-alkyne cycloaddition (SPAAC) provide bioorthogonal conjugation routes that proceed with high yields and chemoselectivity.
Internal conjugation requires the incorporation of modified nucleosides bearing amino, thiol, or click handles at positions within the oligonucleotide sequence, typically at pyrimidine C5 or purine N7 positions where modifications are well tolerated. Internal conjugation sites enable multivalent display of two or more peptide moieties per oligonucleotide molecule, which can enhance cellular uptake and endosomal escape through multivalent binding to cell surface proteoglycans. However, internal modifications may alter target hybridization kinetics and RNase H activation profiles, necessitating empirical screening of conjugation positions to identify sites that preserve antisense activity while maximizing delivery efficiency. The comparative complexity of internal conjugation workflows makes terminal attachment the preferred strategy for most research applications, with internal conjugation reserved for cases where multivalent peptide display is mechanistically required.
Head-to-head comparisons of peptide-ASO conjugates with their unconjugated counterparts have consistently demonstrated 10- to 1000-fold improvements in cellular potency, measured as the concentration required to achieve 50% target knockdown (IC50), across diverse cell types and target genes. In primary hepatocytes, CPP-LNA gapmers targeting apolipoprotein B achieved approximately 50-fold lower IC50 values compared to naked LNA gapmers, while in myotube cultures, Pip6a-PMO conjugates displayed exon-skipping activity at concentrations three orders of magnitude lower than those required for unconjugated PMOs. The magnitude of enhancement is typically greatest for neutral ASO chemistries (PMO and PNA), moderate for partially modified PS-ASOs, and least pronounced for fully PS-modified ASOs that already exhibit some level of protein-mediated cellular uptake.
In vivo studies have further validated the translational potential of peptide-ASO conjugates, with CPP-PMO conjugates demonstrating dystrophin restoration in mdx mice at doses 10- to 50-fold lower than those required for equivalent activity with naked PMOs. Biodistribution analyses have revealed that peptide conjugation alters tissue tropism in predictable ways; for example, arginine-rich CPPs direct conjugates to liver, kidney, and muscle, while peptides incorporating targeting motifs such as RVG (rabies virus glycoprotein peptide) redirect distribution to the brain. The ability to program tissue distribution through peptide design represents a major advantage of the conjugate approach over alternative delivery strategies, enabling tissue-selective modulation of gene expression that minimizes systemic off-target effects while maximizing therapeutic index.
| Property | PMO | PNA | 2'-MOE-PS | LNA-PS |
| Backbone Charge | Neutral | Neutral | Anionic (PS) | Anionic (PS) |
| RNase H Competence | No | No | Yes (gapmer) | Yes (gapmer) |
| Nuclease Resistance | Excellent | Excellent | Good | Excellent |
| Conjugation Ease | High (amine/thiol handles) | Very high (continuous synthesis) | Moderate (charge management) | Moderate (charge management) |
| Typical CPP Enhancement | 100-1000x | 50-500x | 10-100x | 10-100x |
| Primary Application | Splice switching, exon skipping | Antisense, antigene, gene editing | mRNA knockdown | mRNA knockdown |
| Clinical Stage | Phase II/III (naked), Preclinical (CPP) | Preclinical | Approved (naked gapmer) | Preclinical (CPP) |
Table 1. Comparative Properties of ASO Platforms for Peptide Conjugation
Splice-switching oligonucleotide (SSO)-peptide conjugates constitute a specialized subclass of peptide-ASO conjugates designed to redirect pre-mRNA splicing rather than degrade target transcripts. The unique requirement for nuclear localization of SSOs makes peptide-mediated delivery both essential and mechanistically distinct from cytoplasmic ASO delivery, creating specific design considerations for linker stability and intracellular trafficking.
Splice-switching oligonucleotides function by hybridizing to specific sequences within pre-mRNA that are critical for splice site recognition or regulatory element function, thereby preventing the binding of spliceosomal components or splicing regulatory proteins. When SSOs target the splice donor or acceptor sites at exon-intron junctions, they physically block the recruitment of U1 or U2 snRNPs, causing the splicing machinery to skip the adjacent exon and ligate the flanking exons together. This mechanism is exploited for therapeutic exon skipping in DMD, where removal of one or more exons from the mature dystrophin mRNA restores the translational reading frame and enables production of a truncated but partially functional dystrophin protein.
Alternatively, SSOs can be designed to block intronic or exonic splicing silencers (ISS or ESS elements) that normally repress exon inclusion, resulting in enhanced exon inclusion rather than exon skipping. This approach is relevant for spinal muscular atrophy, where SSOs targeting the ISS-N1 element in SMN2 intron 7 promote inclusion of exon 7 and increase production of full-length SMN protein. The splice-switching mechanism requires sustained nuclear concentration of the oligonucleotide at sufficient levels to outcompete the abundant spliceosomal proteins and regulatory factors that bind splicing signals with high affinity, placing premium demands on both delivery efficiency and intracellular stability.
CPP conjugation dramatically enhances the splice-switching activity of oligonucleotides by overcoming the nuclear membrane barrier that limits the passive nuclear accumulation of naked oligonucleotides. In the mdx mouse model of DMD, Pip6a-PMO conjugates targeting exon 23 achieve near-complete exon skipping and widespread dystrophin restoration in skeletal muscles throughout the body, including the diaphragm, a critical respiratory muscle that is poorly reached by naked PMOs. Importantly, the dystrophin protein produced by exon 23-skipped transcripts localizes correctly to the sarcolemma and associates with the dystrophin glycoprotein complex, indicating that the truncated protein retains essential structural and signaling functions.
For exon inclusion strategies, CPP-SSO conjugates targeting the SMN2 ISS-N1 element have demonstrated robust exon 7 inclusion and increased SMN protein expression in SMA patient fibroblasts and in SMA mouse models following systemic administration. Alternative splicing modulation extends beyond monogenic diseases to encompass cancer applications, where CPP-SSOs can redirect splicing of oncogenes such as BCL-X to favor the pro-apoptotic BCL-XS isoform over the anti-apoptotic BCL-XL isoform, inducing selective apoptosis in cancer cells. The growing recognition that aberrant splicing is a hallmark of many cancers has expanded interest in CPP-SSO conjugates as precision oncology tools capable of reprogramming the cancer cell transcriptome.
The mechanistic distinction between splice-switching (nuclear target) and RNase H-mediated knockdown (cytoplasmic or nuclear target) creates fundamentally different delivery requirements that must be addressed through conjugate design. For splice-switching applications, the oligonucleotide must not only reach the cytoplasm but also traverse the nuclear pore complex to access pre-mRNA in the nucleoplasm, a requirement that imposes constraints on conjugate size, charge, and linker stability. Nuclear localization is favored by arginine-rich CPPs that structurally resemble nuclear localization signals, and by linker chemistries that are stable in the reducing environment of the nucleus where disulfide bonds can be cleaved by nuclear glutathione.
In contrast, cytoplasmic ASO mechanisms such as translation blocking can tolerate conjugates that remain in the cytosol or even within endosomal compartments if endosomal escape is sufficient to release active oligonucleotide into the cytoplasm. This distinction has practical implications for linker selection: reducible linkers (disulfide or diselenide) that release free PMO or PNA in the reducing intracellular environment may be preferred for cytoplasmic applications, while non-reducible linkers (amide, triazole, or thioether) that maintain covalent attachment throughout the trafficking pathway may be advantageous for nuclear applications where sustained high local concentration is required. The careful alignment of conjugate design with the subcellular location of the therapeutic target is essential for maximizing activity, and Creative Peptides' Custom Conjugation Service supports researchers in optimizing these design parameters.
| Linker Type | Chemistry | Stability | Release Mechanism | Best Application |
| Disulfide | Cys-S-S-ASO | Stable in plasma | Reductive cleavage (GSH) | Cytoplasmic ASO release |
| Thioether (maleimide) | Cys-S-maleimide-ASO | Stable in all compartments | Non-cleavable | Nuclear splice switching |
| Triazole (click) | Azide-alkyne cycloaddition | Stable in all compartments | Non-cleavable | Nuclear and cytoplasmic |
| Amide | NH2-COOH coupling | Stable in all compartments | Non-cleavable | PNA continuous synthesis |
| Diselenide | Se-Se bridge | Stable in plasma | Reductive cleavage (faster) | Cytoplasmic release (fast) |
| Hydrazone | pH-sensitive C=N | Cleaved at pH 5-6 | Endosomal pH | Endosomal escape-triggered |
Table 2. Linker Chemistries for Peptide-ASO Conjugates
The rational design of peptide-ASO conjugates requires simultaneous optimization of multiple interdependent parameters including linker chemistry, peptide-to-ASO stoichiometry, charge balance, and solubility, all of which must be harmonized to achieve maximal therapeutic activity without compromising conjugate stability or manufacturability. A systematic approach to conjugate design, informed by structure-activity relationship data and analytical characterization, is essential for translating promising in vitro results into robust in vivo performance.
Linker selection critically influences the intracellular fate of peptide-ASO conjugates by determining whether the conjugate remains covalently intact or undergoes cleavage to release free oligonucleotide at specific subcellular locations. For nuclear-targeted applications such as splice switching, non-cleavable linkers (thioether, triazole, or amide) are generally preferred because they maintain the peptide-ASO association throughout the trafficking pathway, potentially enhancing nuclear retention through the peptide's affinity for nuclear components. However, permanently attached peptide may sterically interfere with spliceosomal assembly or regulatory protein binding at the target splice site, creating a trade-off between delivery efficiency and target engagement that must be empirically evaluated for each specific SSO sequence and target.
For cytoplasmic applications, reducible linkers such as disulfide bonds offer the advantage of releasing unencumbered ASO in the reducing environment of the cytoplasm (glutathione concentration approximately 1-10 mM), maximizing target accessibility while preventing peptide-mediated off-target effects. Diselenide linkers provide even faster reductive cleavage kinetics due to the lower bond dissociation energy of Se-Se compared to S-S bonds, potentially enabling more rapid intracellular release but at the cost of reduced synthetic accessibility. pH-sensitive linkers such as hydrazones exploit the acidic environment of endosomal compartments (pH 5-6) to trigger release during or immediately after endosomal escape, an elegant strategy that couples release to the critical trafficking step but requires careful tuning of linker lability to avoid premature cleavage in the slightly acidic tumor microenvironment or in lysosomal compartments.
The stoichiometric ratio of peptide to oligonucleotide in the final conjugate is a critical parameter that affects cellular uptake efficiency, endosomal escape kinetics, solubility, and potential toxicity. Monovalent conjugates with a single peptide attached to each oligonucleotide molecule represent the most common and synthetically tractable format, offering well-defined composition and reproducible activity profiles. However, for oligonucleotides that require particularly high delivery efficiency, bivalent or multivalent conjugates displaying two or more peptide moieties may achieve enhanced cellular uptake through multivalent interactions with cell surface heparan sulfate proteoglycans, analogous to the multivalent binding mechanisms exploited by viral entry proteins.
Bivalent conjugation can be achieved through symmetrical attachment of peptides to both the 5' and 3' termini of the oligonucleotide, or through incorporation of branching linkers that present multiple peptide attachment points at a single terminus. While bivalent constructs often outperform their monovalent counterparts in cellular uptake assays, the increased molecular weight and altered biophysical properties must be weighed against potential reductions in tissue penetration and increased immunogenicity. Stoichiometry control during synthesis is paramount, with HPLC purification essential for isolating the desired monovalent or bivalent species from reaction mixtures that may contain unreacted starting materials and higher-order conjugation products.
The electrostatic interplay between cationic CPPs and anionic ASOs creates both opportunities and challenges for conjugate design. For neutral ASO chemistries (PMO and PNA), the conjugate charge is determined entirely by the peptide component, and high arginine content directly correlates with enhanced cellular uptake but also with increased cytotoxicity at elevated concentrations. Optimal CPP design for neutral ASOs typically involves 6-12 arginine residues, balanced with hydrophobic amino acids that promote membrane interactions and endosomal escape, achieving a favorable therapeutic index that maximizes delivery while minimizing toxicity.
For charged PS-ASOs, the situation is more complex because the polyanionic oligonucleotide can form electrostatic complexes with the cationic peptide, potentially leading to charge neutralization, aggregation, and precipitation at stoichiometric ratios approaching charge equivalence. This phenomenon is particularly problematic for short PS-ASOs (12-16 nucleotides) conjugated to highly cationic CPPs, where solubility issues can preclude biological testing altogether. Strategies to mitigate charge-driven aggregation include the incorporation of polyethylene glycol (PEG) spacers between peptide and ASO to provide steric and hydrophilic shielding, the use of CPPs with moderated charge density through incorporation of neutral hydrophilic amino acids, and careful control of pH and ionic strength during formulation and administration. The systematic optimization of these parameters is essential for developing peptide-ASO conjugates with favorable pharmaceutical properties.
Peptide-ASO conjugates have been applied across a broad spectrum of therapeutic areas, with the most advanced programs targeting neuromuscular diseases where the unmet medical need is high and where the unique delivery properties of CPP conjugates address well-characterized tissue barriers. CNS and oncology applications represent rapidly growing areas where peptide-mediated delivery is being leveraged to overcome the blood-brain barrier and the tumor microenvironment, respectively.
Duchenne muscular dystrophy remains the flagship indication for CPP-PMO conjugate development, driven by the clear mechanistic rationale for exon skipping, the availability of well-characterized animal models (mdx mouse and GRMD dog), and established clinical endpoints including dystrophin protein quantification, six-minute walk distance, and respiratory function. CPP-PMO conjugates have demonstrated consistent superiority over naked PMOs across multiple DMD exons (23, 45, 50, 51, 52, and 53) in the mdx mouse, with dystrophin restoration levels routinely exceeding 30-50% in quadriceps, tibialis anterior, and diaphragm muscles. Cardiac muscle delivery, a critical unmet need in DMD because cardiomyopathy is the leading cause of mortality, has been particularly challenging for naked PMOs but shows meaningful improvement with CPP conjugation, with Pip6a-PMO achieving approximately 20% dystrophin-positive cardiomyocytes after systemic administration.
Translational development has benefited from extensive toxicology studies establishing safety margins for CPP-PMOs in rodents and non-human primates, with the primary dose-limiting toxicity being renal tubular accumulation at high doses that is reversible upon treatment cessation. Several CPP-PMO conjugates have entered clinical development, with early-phase trials evaluating safety, pharmacokinetics, and dystrophin restoration endpoints. The scalability of PMO and peptide synthesis, coupled with established conjugation workflows, supports the clinical and commercial manufacturing requirements for these conjugate therapeutics.
Spinal muscular atrophy exemplifies the CNS delivery challenge that peptide-ASO conjugates are particularly well-suited to address. Nusinersen (Spinraza), an unmodified 2'-MOE splice-switching ASO targeting SMN2, requires intrathecal administration to achieve therapeutic concentrations in the spinal cord and brain, a delivery route that imposes significant clinical burden and limits access to motor neurons in the brainstem and cortex. CPP-ASO conjugates capable of crossing the blood-brain barrier following systemic administration could dramatically improve the therapeutic window and patient convenience for SMA and other CNS indications.
Peptides derived from rabies virus glycoprotein (RVG), which bind the nicotinic acetylcholine receptor on neuronal cells, have been conjugated to SSOs and demonstrated brain delivery and SMN2 exon 7 inclusion following intravenous administration in SMA mouse models. Other brain-targeting peptides, including angiopep-2 (targeting LRP1) and T7 peptide (targeting transferrin receptor), have been evaluated for ASO delivery and shown varying degrees of brain penetration and target engagement. The identification of peptides that achieve clinically meaningful brain-to-plasma ratios while maintaining splice-switching activity at the target pre-mRNA remains an active area of research, with iterative peptide optimization guided by both in vitro blood-brain barrier models and in vivo biodistribution studies.
Oncology applications of peptide-ASO conjugates exploit both splice-switching and knockdown mechanisms to modulate cancer-relevant targets including oncogenes, anti-apoptotic factors, and drug-resistance genes. CPP-SSO conjugates targeting BCL-X splicing redirect the balance from the anti-apoptotic BCL-XL isoform toward the pro-apoptotic BCL-XS isoform, sensitizing cancer cells to chemotherapy and inducing apoptosis as a monotherapy in subsets of hematological and solid tumors. Similarly, CPP-ASO conjugates targeting survivin, an inhibitor of apoptosis protein overexpressed in most human cancers, have demonstrated tumor growth inhibition in xenograft models through combined effects on apoptosis induction and mitotic arrest.
Tumor-homing peptides that recognize receptors or extracellular matrix components selectively expressed in the tumor microenvironment provide an additional layer of targeting beyond the cell-penetrating function, enabling preferential accumulation of ASO conjugates in tumor tissue relative to normal organs. Peptides targeting integrin alpha-v-beta-3 (RGD motif), matrix metalloproteinase substrates, or tumor-associated carbohydrate antigens have been conjugated to therapeutic ASOs and demonstrated improved tumor-to-liver ratios compared to conjugates relying solely on CPP-mediated uptake. The dual-targeting approach, combining tumor-homing and cell-penetrating functionalities within a single peptide or through tandem conjugation of separate targeting and penetrating peptides, represents a sophisticated delivery strategy that Creative Peptides' comprehensive conjugation services are well-positioned to support.
Rigorous analytical characterization of peptide-ASO conjugates is essential for confirming conjugate identity, purity, and structural integrity, as well as for establishing batch-to-batch consistency in research and manufacturing settings. The hybrid peptide-oligonucleotide nature of these conjugates demands a combination of analytical techniques drawn from both peptide and oligonucleotide chemistry, often applied in orthogonal fashion to provide comprehensive quality assessment.
High-performance liquid chromatography (HPLC) is the workhorse technique for peptide-ASO conjugate purification, with the choice of stationary phase and mobile phase conditions dictated by the charge properties of the specific conjugate chemistry. Reversed-phase HPLC using C18 or C8 columns with acetonitrile-water gradients containing ion-pairing agents such as triethylammonium acetate (TEAA) or hexafluoroisopropanol (HFIP) provides high-resolution separation of PMO-peptide and PNA-peptide conjugates from unreacted starting materials, deletion sequences, and other impurities. The neutral backbone of PMOs and PNAs simplifies reversed-phase method development compared to charged PS-ASOs, as the absence of phosphate charge eliminates the need for extensive ion-pairing optimization.
Ion-exchange chromatography (IEX) is particularly valuable for PS-ASO-peptide conjugates, where the phosphate backbone charge provides a strong retention mechanism on anion-exchange resins. The addition of a cationic peptide to the anionic oligonucleotide results in a net charge shift that alters IEX retention time in a predictable manner, enabling separation of unconjugated ASO, monovalent conjugate, and bivalent conjugate species based on their distinct charge states. For challenging separations, orthogonal purification combining IEX and RP-HPLC in a two-dimensional workflow can resolve conjugates that co-elute under single-dimension conditions, providing the high purity (typically greater than 95%) required for reliable biological testing. Creative Peptides employs validated HPLC and IEX methods as part of its ASO Peptide Conjugate quality control workflow.
Mass spectrometry provides definitive confirmation of peptide-ASO conjugate molecular weight and, by extension, conjugate identity, stoichiometry, and purity. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is widely used for rapid molecular weight determination of PMO and PNA conjugates, offering high sensitivity, tolerance to salts and buffers, and straightforward spectra dominated by singly charged ions that simplify data interpretation. The neutral character of PMOs and PNAs makes them particularly amenable to MALDI-TOF analysis, typically yielding molecular weight accuracy within 0.1% of the theoretical mass.
Electrospray ionization (ESI) mass spectrometry, often coupled with liquid chromatography (LC-MS), provides complementary information including multiply charged ion envelopes that enable deconvolution to accurate molecular weights, as well as the ability to characterize impurities and degradation products present at low levels. ESI-MS is better suited than MALDI-TOF for PS-ASO-peptide conjugates, where the phosphate backbone charge facilitates ionization and where sodium adduct formation (a common MALDI artifact for phosphorothioates) is less problematic. Tandem mass spectrometry (MS/MS) can provide sequence confirmation of both the peptide and oligonucleotide components, though the fragmentation behavior of modified oligonucleotides differs substantially from that of peptides and requires specialized interpretation expertise.
Analytical characterization of conjugate identity and purity must be complemented by functional validation in relevant cellular assays to confirm that the conjugation process has preserved the intended biological activity. For splice-switching conjugates, reverse transcription PCR (RT-PCR) using primers flanking the targeted exon provides a direct readout of exon-skipping or exon-inclusion efficiency, with the ratio of skipped to unskipped transcript quantified by capillary electrophoresis or digital droplet PCR. Dose-response experiments across a concentration range spanning three to four orders of magnitude enable determination of EC50 values that facilitate comparison across conjugate variants and benchmarking against unconjugated control oligonucleotides.
For knockdown ASOs, target mRNA levels are quantified by RT-qPCR, while target protein levels are assessed by western blot or ELISA to confirm that mRNA reduction translates to protein knockdown. Functional validation should be performed in cell lines that are biologically relevant to the intended therapeutic application, as cell-type-specific differences in endocytic machinery, endosomal trafficking, and intracellular reducing potential can significantly influence conjugate activity. The inclusion of appropriate controls, including unconjugated ASO, peptide alone, and scrambled sequence conjugates, is essential for attributing observed activity specifically to the sequence-dependent antisense mechanism rather than to non-specific effects of the peptide or oligonucleotide components.
The successful development of peptide-ASO conjugates, from early-stage research through preclinical development and ultimately clinical translation, depends on reliable access to high-quality peptide and oligonucleotide synthesis, robust conjugation chemistry, and comprehensive analytical characterization. For academic laboratories and biotechnology companies engaged in peptide-ASO conjugate research, partnering with an experienced peptide manufacturer offers significant advantages in terms of synthetic expertise, analytical infrastructure, and scalability that are difficult to replicate in-house. Creative Peptides has established itself as a trusted provider of peptide synthesis and conjugation services, supporting research programs across the full spectrum of peptide-oligonucleotide conjugate applications.
Creative Peptides offers end-to-end solutions that span CPP design and synthesis, PMO and ASO procurement, covalent conjugation using optimized linker chemistries (thioether, disulfide, click chemistry, and amide coupling), HPLC purification to high purity standards, and analytical characterization including mass spectrometry and HPLC analysis. For projects requiring customized approaches, the company's Custom Conjugation Service provides flexible options for exploring novel conjugation chemistries, optimizing peptide-to-ASO stoichiometry, and scaling up successful lead conjugates. Researchers benefit from batch-to-batch consistency, detailed certificates of analysis, and the ability to rapidly iterate on conjugate designs without investing in specialized synthesis and purification equipment.
For programs advancing toward preclinical development, Creative Peptides supports scale-up from milligram research quantities to gram-scale production, maintaining purity and activity specifications throughout the scale-up process. The company's experience across diverse ASO chemistries, including PMO, PNA, 2'-MOE, LNA, and PS-modified oligonucleotides, ensures that conjugation protocols are matched to the specific requirements of each oligonucleotide platform. Whether the goal is to validate a novel CPP sequence for exon skipping, to compare linker chemistries for intracellular release kinetics, or to produce material for in vivo efficacy and toxicology studies, Creative Peptides provides the technical expertise and manufacturing reliability that modern peptide-ASO conjugate research demands. To discuss your specific conjugate requirements, please contact our technical team for a consultation on project design, timeline, and quotation.
Peptide conjugation dramatically enhances the cellular uptake and endosomal escape of antisense oligonucleotides, improving potency by 10- to 1000-fold compared to naked ASOs. This is particularly critical for neutral-backbone ASOs (PMO and PNA) that otherwise exhibit negligible spontaneous cellular permeability.
PMOs and PNAs are the most straightforward platforms for peptide conjugation due to their neutral backbones, which simplify conjugation chemistry and avoid charge-driven aggregation. However, 2'-modified PS-ASOs can also be successfully conjugated with appropriate charge management strategies.
Non-cleavable linkers such as thioether (maleimide), triazole (click chemistry), or amide bonds are generally preferred for nuclear splice-switching applications because they maintain the peptide-ASO association throughout intracellular trafficking and enhance nuclear retention.
Purity is assessed by a combination of HPLC (reversed-phase or ion-exchange), mass spectrometry (MALDI-TOF or ESI-LC/MS), and functional assays including RT-PCR for splice-switching activity or RT-qPCR for target knockdown. Conjugates are typically purified to greater than 95% purity for biological testing.
